Thrombin Mutant W215A/E217A Treatment Improves Neurological Outcome and Reduces Cerebral Infarct Size in a Mouse Model of Ischemic Stroke | Zendy

Michelle A. BernyLang | Zendy; Sawan Hurst | Zendy; Erik I. Tucker | Zendy; Leslie A. Pelc | Zendy; Ruikang K. Wang | Zendy; Patricia D. Hurn | Zendy; Enrico Di | Zendy; Owen J. T. McCarty | Zendy; András Gruber | Zendy

Open Access

Thrombin Mutant W215A/E217A Treatment Improves Neurological Outcome and Reduces Cerebral Infarct Size in a Mouse Model of Ischemic Stroke

Author(s) -

Michelle A. BernyLang,

Sawan Hurst,

Erik I. Tucker,

Leslie A. Pelc,

Ruikang K. Wang,

Patricia D. Hurn,

Enrico Di,

Owen J. T. McCarty,

András Gruber

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.603811

Subject(s) - medicine , middle cerebral artery , hemostasis , tissue plasminogen activator , stroke (engine) , anesthesia , plasminogen activator , ischemia , cerebral infarction , occlusion , cardiology , mechanical engineering , engineering

Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E217A (WE) is antithrombotic without hemostasis impairment in primates. Therefore, we investigated the outcome of WE-treated experimental ischemic stroke in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research